Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral vaccines - Innogenetics

Drug Profile

Research programme: viral vaccines - Innogenetics

Alternative Names: ED 002; ED 009; EP 2220; EP 2230; GNI-103; GNI-105

Latest Information Update: 24 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genencor International; Pharmexa-Epimmune
  • Developer Innogenetics; Pharmexa-Epimmune
  • Class Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C; Human papillomavirus infections

Most Recent Events

  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
  • 09 Sep 2008 Innogenetics has been acquired by Solvay Pharmaceuticals
  • 05 Sep 2007 Preclinical development of vaccine candidates ED 002 and ED 009 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top